NYSE:BMY

Bristol Myers Squibb is a global specialty biopharmaceutical company. It focuses on diseases such as oncology, cardiovascular, immunoscience and fibrosis. The company’s planned acquisition of Celgene will further position it as a leading biopharmaceutical company, expanding its oncology and immunoscience portfolios. About 56% of Bristol Myers’ 2018 revenues were derived from the U.S., 25% from Europe and 19% from the rest of the world. More than 90% of Bristol Meyers’ total sales are from prioritized brands, which include Opdivo, Eliquis, Orencia, Sprycel, Yervoy, and Empliciti, while established brands like Baraclude and others comprise the rest of the revenues. Opdivo and Eliquis are Bristol Myers’ leading brands. Opdivo was the first Immuno-Oncology therapy to be approved in China in 2018. Bristol Myers continues to grow through continuous approvals for new medicines and formulations of currently marketed medicines in major markets. The company’s large IO portfolio positions it well for the future.